When a patient is diagnosed with a bacterial infection, medical staff need to identify the species attacking the body before it can be treated. The problem is, this process can take a few days and may ...
Lonza entered into two new collaborations with McSAF and Cristal Therapeutics to expand its bioconjugates offering. The collaborations are geared to enable the integration of two novel conjugation ...
Lonza and Singzyme will use Singzyme’s enzymatic conjugation platform to develop novel bioconjugates. Lonza and Singzyme, a biotechnology company specializing in developing enzymes for protein ...
This panel will present a focused playbook for biopharma patent practitioners allowing them to protect the full scope of innovation reflected in the biologic development process. The discussion will ...
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC The extended relationship builds ...
WuXi Biologics and WuXi STA have established a joint venture company named WuXi XDC to provide contract development and manufacturing of bioconjugates, including antibody-drug conjugates. WuXi ...
Lonza and AbTis, a Korean biotech company focusing on the development of antibody drug conjugates (ADCs), agreed to work together on advancing the precision of bioconjugation strategies for novel ...
A technique developed by Miami University associate professors of chemistry and biochemistry Dominik Konkolewicz and Rick Page may help enable more rapid and efficient development of new materials for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results